EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Implementation of tax provisions of the ACA and tax reform policies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| JONAH C HOUTS | — |
| EMILY A KATZ | — |
| GARY J KLINE | — |
| SERGIO SANTIVIAGO | — |
Health Issues HCR
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues, including biosimilars. Reforms to Medicaid and Exchange markets.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| JONAH C HOUTS | — |
| EMILY A KATZ | — |
| GARY J KLINE | — |
| SERGIO SANTIVIAGO | — |
Defense DEF
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| MICHAEL DONNELLY | — |
| JONAH C HOUTS | — |
| EMILY A KATZ | — |
| GARY J KLINE | — |
| LISA CHRISTINE LE GETTE | — |
| SERGIO SANTIVIAGO | — |
Medicare/Medicaid MMM
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| JONAH C HOUTS | — |
| EMILY A KATZ | — |
| GARY J KLINE | — |
| LISA CHRISTINE LE GETTE | — |
| SERGIO SANTIVIAGO | — |
Pharmacy PHA
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER DAVIS | — |
| JONAH C HOUTS | — |
| EMILY A KATZ | — |
| GARY J KLINE | — |
| LISA CHRISTINE LE GETTE | — |
| SERGIO SANTIVIAGO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.